Sealy Institute for Drug Discovery


UTMB has a stellar track record in countermeasure development against emerging viruses through partnership with government and industry. In response to the recent emergence of Ebola virus and SARS-CoV-2, UTMB has played a pivotal role in developing the first FDA-approved therapy and vaccine. To expand the success to other disease areas, UTMB launched the Institute for Drug Discovery in September 2021.

The mission of the Institute for Drug Discovery is to improve human health by:

  • Discovering and developing clinical drug candidates
  • Advancing knowledge of drug discovery
  • Training next-generation drug hunters


The Sealy Institute for Drug Discovery and Development (SIDD) is established to enable a highly qualified and talent research team with expertise in drug discovery and development to work closely with the leading UTMB investigators working in the fields of infectious diseases, neuroscience, aging, and other disciplines to take advantage of the growing opportunities provided by the emerging discoveries and new biological insights, enabling the discovery and development of novel therapeutics. This integrated academic drug discovery program will cover target discovery and screening, lead generation and validation in novel preclinical for both small molecules and biologics.